WSTO9 (TOOKAD) mediated photodynamic therapy as an alternative modality in the treatment of prostate cancer

Qun Chen; Zheng Huang; David L. Luck; Jill Beckers; Pierre-Herve Brun; Brian C. Wilson; Avigdor Scherz; Yoram Salomon; Fred W. Hetzel

doi:10.1117/12.469351

6 June 2002 WSTO9 (TOOKAD) mediated photodynamic therapy as an alternative modality in the treatment of prostate cancer

Qun Chen, Zheng Huang, David L. Luck, Jill Beckers, Pierre-Herve Brun, Brian C. Wilson, Avigdor Scherz, Yoram Salomon, Fred W. Hetzel

Author Affiliations +

Proceedings Volume 4612, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XI; (2002) https://doi.org/10.1117/12.469351
Event: International Symposium on Biomedical Optics, 2002, San Jose, CA, United States

Abstract

Photodynamic therapy (PDT) utilizes optical energy to activate a pre-administered photosensitizer drug to achieve a localized tumor control. In the presented study, PDT mediated with a second-generation photosensitizer, WST09 (TOOKAD, Steba Biotech, The Netherlands), is investigated as an alternative therapy in the treatment of prostate cancer. In vivo canine prostate is used as the animal model. PDT was performed by irradiating the surgically exposed prostates both superficially and interstitially with a diode laser (763 nm) to activate the intra-operatively i.v. infused photosensitizer. During light irradiation, tissue optical properties, and temperature were monitored. During the one-week to 3-month period post PDT treatment, the dogs recovered well with little or no complications. The prostates were harvested and subjected to histopathological evaluations. Maximum lesion size of over 3 cm in dimension could be achieved with a single treatment, suggesting the therapy is extremely effective in destroying prostatic tissue. Although we found there was loss of epithelial lining in prostatic urethra, there was no evidence it had caused urinary tract side effects as reported in those studies utilizing transurethral irradiation. In conclusion, we found second generation photosensitizer WST09 mediated PDT may provide an excellent alternative to treat prostate cancer.

Citation Download Citation

Qun Chen, Zheng Huang, David L. Luck, Jill Beckers, Pierre-Herve Brun, Brian C. Wilson, Avigdor Scherz, Yoram Salomon, and Fred W. Hetzel "WSTO9 (TOOKAD) mediated photodynamic therapy as an alternative modality in the treatment of prostate cancer", Proc. SPIE 4612, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XI, (6 June 2002); https://doi.org/10.1117/12.469351

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available